Thrombocythemia and polycythemia in patients younger than 20 years at diagnosis: clinical and biologic features, treatment, and long-term outcome

Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet

(2011) Tiziano Barbui et al.   JOURNAL OF CLINICAL ONCOLOGY

A retrospective study on 226 polycythemia vera patients: impact of median hematocrit value on clinical outcomes and survival improvement with anti-thrombotic prophylaxis and non-alkylating drugs

(2010) Elena Crisà et al.   ANNALS OF HEMATOLOGY

Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia

(2010) A. Alvarez-Larran et al.   BLOOD

Long-term follow-up of essential thrombocythemia in young adults: treatment strategies, major thrombotic complications and pregnancy outcomes. A study of 76 patients

(2010) F. Palandri et al.   HAEMATOLOGICA

Leukocytosis is associated with poor survival but not with increased risk of thrombosis in essential thrombocythemia: a population-based study of 311 patients

(2010) F Girodon et al.   LEUKEMIA

Long-term follow-up of 386 consecutive patients with essential thrombocythemia: Safety of cytoreductive therapy

(2009) Francesca Palandri et al.   AMERICAN JOURNAL OF HEMATOLOGY

Outcome of 122 pregnancies in essential thrombocythemia patients: A report from the Italian registry

(2009) Lorella Melillo et al.   AMERICAN JOURNAL OF HEMATOLOGY

Predictors of pregnancy outcome in essential thrombocythemia: a single institution study of 63 pregnancies

(2009) Naseema Gangat et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Hereditary thrombocytosis caused by MPLSer505Asn is associated with a high thrombotic risk, splenomegaly and progression to bone marrow fibrosis

(2009) L. Teofili et al.   HAEMATOLOGICA

Evidence for a founder effect of the MPL-S505N mutation in eight Italian pedigrees with hereditary thrombocythemia

(2009) K. Liu et al.   HAEMATOLOGICA

Influence of the JAK2 V617F mutation and inherited thrombophilia on the thrombotic risk among patients with essential thrombocythemia

(2009) V. De Stefano et al.   HAEMATOLOGICA

JAK2V617Fmutation in essential thrombocythemia: correlation with clinical characteristics, response to therapy and long-term outcome in a cohort of 275 patients

(2009) Francesca Palandri et al.   LEUKEMIA & LYMPHOMA

Essential thrombocythemia, polycythemia vera, and myelofibrosis: Current management and the prospect of targeted therapy

(2008) Ayalew Tefferi   AMERICAN JOURNAL OF HEMATOLOGY

Clinical and molecular characterisation of a prospectively collected cohort of children and adolescents with polycythemia vera

(2008) Holger Cario et al.   BRITISH JOURNAL OF HAEMATOLOGY

Effect of JAK2 V617F on thrombotic risk in patients with essential thrombocythemia: measuring the uncertain

(2008) P. D. Ziakas   HAEMATOLOGICA

A novel heterozygous HIF2AM535I mutation reinforces the role of oxygen sensing pathway disturbances in the pathogenesis of familial erythrocytosis

(2008) M. Martini et al.   HAEMATOLOGICA

Childhood polycythemia vera and essential thrombocythemia: does their pathogenesis overlap with that of adult patients?

(2008) L. Teofili et al.   HAEMATOLOGICA

Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients

(2008) F. Passamonti et al.   HAEMATOLOGICA

Is JAK2 V617F mutation more than a diagnostic index?

(2008) Issa J. Dahabreh et al.   LEUKEMIA RESEARCH